Geron (GERN) Stock Soars as FDA Lifts Hold

Shares of Geron Corporation (GERN) were up +0.86 or +33.07 percent to $3.46 per share in pre-market trading on Thursday, after the company announced early this morning that the FDA had notified Dr. Ayalew Tefferi of the Mayo Clinic the partial hold on clinical trials for Geron’s treatment of myelofibrosis, imetelstat, had been lifted. Geron Read the full article... Read the rest of Geron (GERN) Stock Soars as FDA Lifts Hold at InvestorGuide.com .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.